Features of the patients included in the present study
| Features . | n . |
|---|---|
| Patients, total | 33 |
| Median age, y (range) | 52 (18-79) |
| Male to female ratio | 19:14 |
| Disease phase/type | |
| CML | 18 |
| Chronic phase | 9 |
| Accelerated phase | 1 |
| Myeloid blast crisis | 3 |
| Lymphoid blast crisis | 5 |
| Ph+ ALL | 15 |
| No. of lines of TKI therapy received | |
| 2 | 22 |
| 3 | 8 |
| 4 or more | 3 |
| Features . | n . |
|---|---|
| Patients, total | 33 |
| Median age, y (range) | 52 (18-79) |
| Male to female ratio | 19:14 |
| Disease phase/type | |
| CML | 18 |
| Chronic phase | 9 |
| Accelerated phase | 1 |
| Myeloid blast crisis | 3 |
| Lymphoid blast crisis | 5 |
| Ph+ ALL | 15 |
| No. of lines of TKI therapy received | |
| 2 | 22 |
| 3 | 8 |
| 4 or more | 3 |